Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 7;19(11):3505.
doi: 10.3390/ijms19113505.

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer

Affiliations
Review

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer

Shravanti Macherla et al. Int J Mol Sci. .

Abstract

Immune checkpoint blockade (ICB) with programmed cell death protein-1(PD-1)/programmed death ligand -1(PD-L1) antibodies has revolutionized the management of several cancers, especially non-small cell lung cancer, melanoma, urothelial, and renal cancer. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers associated with high morbidity and mortality. Based on available data, it's obvious that ICB has limited success in PDACs, which can be explained by the low immunogenicity and immunosuppressive tumor microenvironment of these tumors. In this review article, we focus on PD-L1 expression and microsatellite instability (MSI) in PDAC, and their roles as prognostic and predictive markers. We also discuss data supporting combination therapies to augment cancer immunity cycle. Combining anti-PD-1/PD-L1 agents with other modalities such as vaccines, chemotherapy, and radiation could potentially overcome resistance patterns and increase immune responsiveness in PDAC.

Keywords: microsatellite instability; pancreatic adenocarcinoma; programmed death ligand.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Surveillance, Epidemiology, and End results (SEER) Cancer Stat Fcts: Pancreatic Cancer. [(accessed on 18 October 2018)]; Available online: https://seer.cancer.gov/statfacts/html/pancreas.html.
    1. Liu Q., Liao Q., Zhao Y. Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int. 2017;17:68. doi: 10.1186/s12935-017-0437-3. - DOI - PMC - PubMed
    1. Zheng L., Xue J., Jaffee E.M., Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 2013;144:1230–1240. doi: 10.1053/j.gastro.2012.12.042. - DOI - PMC - PubMed
    1. Moertel C.G. Chemotherapy of gastrointestinal cancer. N. Engl. J. Med. 1978;299:1049–1052. doi: 10.1056/NEJM197811092991906. - DOI - PubMed